This clear and concise piece touches on many of our criteria, but only lightly. A competing Wall Street Journal piece explained more fully how this study differs from the gold standard of a clinical trial and how this study in particular could have missed important distinctions between patients. We appreciated the story’s generally cautious tone.
When the evidence to support one treatment over another is so marginal, reporters have a duty to full explore all the implications of a more invasive and more costly procedure over the standard treatment. Most coverage of this retrospective, observational study could have taken a little more time to delve into the study’s limitations.
This story, along with the Associated Press and Wall Street Journal stories we reviewed, did not include information about costs.
The story quantified the benefits two different ways. It says, “Four years after the procedure, patients over 65 who had coronary artery bypass surgeries (called CABG or “cabbages”) were almost 20 percent less likely to die. Put another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.”
This would have been a good time to use the Number Needed to Treat statistic. Overall, the story made a good effort to give readers numbers in a way they could easily understand.
This story, along with the Associated Press we reviewed, failed to mention harms. We did appreciate, though, that NPR noted that “doctors and patients have voted with their feet in favor of the less-invasive procedure — clearing clogged arteries and propping them open with tiny scaffolds called stents.”
The story could have done more here, but, given the space devoted to the topic, we were happy to see some mention of the study’s limitations saying that only “studies that randomly assign comparable patients to surgery or stenting can” answer the question of which type of procedure is better for patients. The story also notes that the difficulty in doing randomized trials “calls into question the ultimate relevance of the findings.”
This story did not engage in disease mongering.
Dr. Laura Mauri, who wrote an accompanying editorial, has a few words of caution about patients switching from stents to open-heart surgery. And the story nicely points out that “Mauri is an interventional cardiologist – i.e., a specialist who does coronary stenting – at Brigham and Women’s Hospital in Boston.” That doesn’t mean that Mauri would recommend stents against the evidence, but it helps readers understand her perspective.
The study itself was a comparison between two treatment paths, and the story explains that. A mention of drug treatment as an option would have been welcome.
Unlike the Wall Street Journal story and the Associated Press story we reviewed, this story at least mentioned the fact that more people have been opting for stents instead of bypass surgery.
Adequate: “Studies have been inconclusive” … “Now the biggest collection of cases so far comes out in favor of surgery”
The story does not rely on a press release.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like